Single-Use Bioreactors Market worth $9.1 billion by 2029 driven by Rising Tech Innovations | MarketsandMarkets™

Browse in-depth TOC on "Single Use Bioreactors Market"

572 - Tables
58 - Figures
442 - Pages

Sartorius AG: Leading Provider of Single-Use Bioreactor Solutions

Sartorius AG is a prominent player in the single-use bioreactors market, catering to biopharmaceutical and pharmaceutical companies, CMOs, and CROs. The company stands out for its comprehensive range of customer-centric, technology-driven solutions and significant investments in R&D. Its extensive product lineup, which includes high-quality single-use bioreactors, is a key factor in its growing market share. Sartorius AG's robust global presence and ongoing expansion in both developed and emerging markets position it for continued growth in the single-use bioreactors sector during the forecast period.

Danaher Corporation: Key Innovator in Single-Use Bioreactors

Danaher Corporation, through its subsidiary Cytiva, offers advanced cell culture, filtration, separation, and purification technologies for the medical, biopharmaceutical, and food & beverage industries. Its strong portfolio of single-use bioreactor solutions makes it a leading player in the market. Danaher's bioprocessing technologies facilitate the development and commercialization of drugs, plasma, and vaccines, underscoring its significant role in the single-use bioreactors market.

Thermo Fisher Scientific, Inc.: Comprehensive Single-Use Bioreactor Solutions Provider

Thermo Fisher Scientific, Inc. provides a broad range of single-use bioreactor products, effectively addressing diverse market needs. As a leading market player, Thermo Fisher leverages its extensive product offerings and strong market presence to influence trends and customer preferences. Continuous investment in R&D enables the company to stay at the cutting edge of technological advancements, addressing emerging challenges and opportunities in bioprocessing.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=49113750

Product Segmentation: Single-Use Bioreactor Systems Lead the Market

In 2023, the single-use bioreactors market is divided into several product categories: single-use bioreactor systems, single-use media bags, single-use assemblies, and other products (such as single-use vessels, sensors, tubing, connectors, software, control systems, and probes). The single-use bioreactor systems segment held the largest market share due to their lower initial investment requirements, reduced operational costs from simplified processes, and minimal environmental impact thanks to recyclable components. These advantages have significantly boosted the adoption of single-use bioreactor systems in biopharmaceutical applications.

Type Segmentation: Stirred-Tank Bioreactors Dominate

The single-use bioreactors market is segmented by type into stirred-tank, wave-induced, bubble-column, and other bioreactors (including hybrid designs and bioreactors with vertically perforated discs). In 2023, stirred-tank bioreactors represented the largest segment. Known for their versatility and scalability, stirred-tank bioreactors are extensively used in the pharmaceutical and biotechnology sectors. Their impeller-driven design ensures even distribution of gases and nutrients, making them ideal for producing recombinant proteins, vaccines, and monoclonal antibodies.

Molecule Type Segmentation: Monoclonal Antibodies Lead

The single-use bioreactors market is also segmented by molecule type into monoclonal antibodies (mAbs), vaccines, stem cells, gene-modified cells, and therapeutic proteins & peptides. In 2023, the monoclonal antibodies segment had the largest share, driven by the expanding pharmaceutical R&D pipeline, increasing cancer incidence, and rising demand for cancer therapies.

Cell Type Segmentation: Mammalian Cells Prevail

In terms of cell types, the market is divided into mammalian cells, bacterial cells, yeast cells, and other cells (such as insect and plant cells). The mammalian cells segment held the largest market share in 2023. This is due to the widespread use of mammalian cells in bioprocessing, known for their sophisticated metabolic functions, which drive the segment's growth.

Application Segmentation: Bioproduction Leads

The market is segmented by application into bioproduction, process development, and research & development (R&D). The bioproduction segment accounted for the largest share in 2023, attributed to the growing use of single-use bioreactors in biomanufacturing, increased regulatory approvals for biopharmaceuticals, the rise of biosimilars, and patent expirations of blockbuster drugs.

End-User Segmentation: Pharmaceutical & Biotechnology Companies Dominate

Based on end users, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs) & contract manufacturing organizations (CMOs), and academic & research institutes. The pharmaceutical & biotechnology companies segment was the largest in 2023 due to heightened R&D activities and increased production of biologics and biosimilars.

Regional Insights: North America and Asia Pacific Lead

The market is divided by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America held the largest market share, followed by Europe. North America's substantial market share is driven by the presence of major players and growing demand for personalized medicine and biologics. Meanwhile, the Asia Pacific region is anticipated to experience the highest compound annual growth rate (CAGR), fueled by the rising demand for biosimilars, expanding biopharmaceutical manufacturing capacities, and a growing contract manufacturing sector.

For more information, inquire now! Inquire Now

Related Reports:

Single Use Bioprocessing Market

Biologics Safety Testing Market

Single Use Assemblies Market

Sterile Filtration Market

Bioprocess Containers Market

Get access to the latest updates on Single Use Bioreactors Companies and Single Use Bioreactors Market Share

About MarketsandMarkets™:

MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com/

Logo: https://mma.prnewswire.com/media/1951202/4609423/MarketsandMarkets.jpg

View original content:https://www.prnewswire.co.uk/news-releases/single-use-bioreactors-market-worth-9-1-billion-by-2029-driven-by-rising-tech-innovations--marketsandmarkets-302212061.html